HIV/AIDS News

Genvoya, a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide, was approved by the FDA today for the treatment of HIV-1 infection in patients aged 12 years or older, according to a press release.

Recent data on three nucleoside reverse-transcriptase inhibitors demonstrated low toxicity and good clinical, immunological and virological responses in HIV-infected children and adolescents from Africa, according to a recent study.

Pregnant, HIV-positive women who took tenofovir disoproxil fumarate during their third trimester gave birth to babies with lower bone mineral content, compared with women not taking the drug, according to data from a recent NIH-funded study.

WHO issued an early release of the organization’s 2016 guidelines, recommending that all patients with HIV should immediately initiate ART regardless of their CD4 cell counts and that all patients at high risk for HIV should receive daily pre-exposure prophylaxis.

Despite all of the recent gains and progress made in the fight against HIV/AIDS in Africa, the situation is still “not under control,” according to U.S. Ambassador Deborah L. Birx, MD, global AIDS coordinator and special representative for Global Health Diplomacy at the State Department.

The FDA approved a new pediatric weight band for atazanavir oral powder, according to a press release. The revised label includes dosing recommendations for patients at least 3 months of age who weigh a minimum of 5 kg.

A potential failure to follow proper sterilization procedures for surgical instruments at a Seattle Children’s Hospital clinic has prompted hospital officials to issue a warning that up to 12,000 pediatric patients may be at risk for infection, according to a news release.

Gay and bisexual teenage boys were unlikely to undergo HIV testing, according to research published in the Journal of Adolescent Health.

Highly active ART before or during pregnancy may increase the risk for adverse birth outcomes, such as preterm delivery and low birth weight, compared with other ART for HIV.

Highly active ART before or during pregnancy may increase the risk for adverse birth outcomes, such as preterm delivery and low birth weight, compared with other ART for HIV.